Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1502321 | 0.84 | ALDH1A1 (0.48) | ALDH1A1TP53CA1CA2CYP3A4 | |
| SCHEMBL107882 | 0.83 | FLT1 (0.51) | ALDH1A1TP53MYCMAOBKDM4E | |
| SCHEMBL402387 | 0.83 | ALDH1A1 (0.63) | ALDH1A1TP53CA1CA2CYP3A4 | |
| SCHEMBL3922668 | 0.83 | ALDH1A1 (0.47) | ALDH1A1TP53CA1CA2CYP3A4 | |
| SCHEMBL1999332 | 0.81 | ALDH1A1 (0.59) | ALDH1A1TP53CA1CA2CYP3A4 | |
| SCHEMBL1929477 | 0.80 | ALDH1A1 (0.68) | ALDH1A1KDM4EGAAGLAKCNMA1 | |
| SCHEMBL1311663 | 0.80 | MEN1 (0.53) | ALDH1A1GAAPOLBTSHRSMN1; SMN2 | |
| SCHEMBL9153003 | 0.80 | MCL1 (0.48) | ALDH1A1CYP3A4KDM4ETSHR | |
| SCHEMBL15936062 | 0.80 | ESR2 (0.56) | — | |
| SCHEMBL654794 | 0.79 | ALDH1A1 (0.52) | ALDH1A1TP53CA1CA2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107935966-B | Production method of dimethomorph | 江苏恒隆作物保护有限公司 | 2021-04-09 | — | — | CN | claimed |
| JP-11222483-A | — | — | None | — | — | JP | disclosed |
| CN-114213310-B | Indoline compound and derivative thereof, preparation method, pharmaceutical composition and application | 中国药科大学 | 2024-02-23 | — | — | CN | disclosed |
| WO-2023125473-A1 | INDOLINE COMPOUNDS AND DERIVATIVES THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国药科大学 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023125473-A1 | INDOLINE COMPOUNDS AND DERIVATIVES THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国药科大学 | 2023-07-06 | — | — | WO | disclosed |
| CN-114213310-A | Indoline compound and derivative, preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2022-03-22 | — | — | CN | disclosed |
| CN-107935966-B | Production method of dimethomorph | 江苏恒隆作物保护有限公司 | 2021-04-09 | — | — | CN | disclosed |
| US-10479779-B2 | Substituted pyrroles active as kinases inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-11-19 | — | — | US | disclosed |
| US-10479778-B2 | Substituted pyrroles active as kinases inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-11-19 | — | — | US | disclosed |
| US-10479778-B2 | Substituted pyrroles active as kinases inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-11-19 | — | — | US | disclosed |
| WO-2009140500-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20090274652-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| US-20090274652-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| WO-2009129109-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2008060927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| JP-H11222483-A | 2,4-DIPHENYL-2-OXA (THIA) ZOLINE DERIVATIVE AND HERBICIDE WITH THE SAME AS ACTIVE INGREDIENT | YASHIMA CHEMICAL IND CO LTD | 1999-08-17 | — | — | JP | disclosed |
| US-4942163-A | LEUKEMIA | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-07-17 | — | — | US | disclosed |
| US-4016274-A | TRANQUILIZERS AND ANTICONVULSANT AGENTS | RHONE-POULENC S.A. (FR) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | ALDH1A1 623/4885TP53 1811/4885CA1 4242/4885 |
| US-20090274652-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | ALDH1A1 623/4885TP53 1811/4885CA1 4242/4885 |
| US-10479779-B2 | Substituted pyrroles active as kinases inhibitors | JAK2, JAK1, JAK3 | ALDH1A1 3525/4885TP53 1336/4885CA1 4769/4885 |
| US-10479778-B2 | Substituted pyrroles active as kinases inhibitors | JAK2, JAK1, JAK3 | ALDH1A1 3525/4885TP53 1336/4885CA1 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.